US 11117975
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
granted A61KA61K2039/505A61K38/00
Quick answer
US patent 11117975 (Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K38/212, A61K39/39558